KEYNOTE-022:帕博利珠单抗联合曲美替尼治疗BRAF野生型黑色素瘤或晚期实体瘤
1/2期KEYNOTE-022研究第4、5部分评估帕博利珠单抗联合曲美替尼在实体瘤及BRAF野生型黑色素瘤中的最大耐受剂量、安全性和疗效。共入组42例,同时给药最大耐受剂量为帕博利珠单抗200 mg每3周联合曲美替尼1.5 mg每日一次(2周曲美替尼导入),间歇给药最大耐受剂量为帕博利珠单抗200 mg每3周联合曲美替尼2 mg每日一次(2周导入)。联合方案抗肿瘤活性有限,间歇给药的客观缓解率数值上高于同时给药,安全性可控。
要点
- 同时给药最大耐受剂量为帕博利珠单抗200 mg每3周联合曲美替尼1.5 mg每日一次,含2周曲美替尼1.5 mg每日一次导入。
- 间歇给药最大耐受剂量为帕博利珠单抗200 mg每3周联合曲美替尼2 mg每日一次,含2周曲美替尼2 mg每日一次导入。
- 间歇给药客观缓解率数值上高于同时给药,联合方案抗肿瘤活性有限且安全性可控。
核心结论
- 同时给药与间歇给药的最大耐受剂量均已确定,联合方案抗肿瘤活性有限,间歇给药客观缓解率数值上高于同时给药,安全性可控。
研究设计与样本
- 1/2期KEYNOTE-022研究第4、5部分,评估帕博利珠单抗联合曲美替尼在实体瘤及BRAF野生型黑色素瘤中的最大耐受剂量、安全性和疗效。
- 共入组42例患者,接受间歇或同时给药,采用3+3剂量递增后进行剂量确认。
- 同时给药为曲美替尼导入2或4周后帕博利珠单抗每3周联合曲美替尼每日一次;间歇给药为曲美替尼导入2周后帕博利珠单抗联合间歇曲美替尼(停1周/用2周)。
主要发现
- 初始剂量水平未发生剂量限制性毒性;后续剂量水平中38例可评估患者有10例发生剂量限制性毒性。
- 同时给药DL2a组5例(31%)发生3/4级治疗相关不良事件,客观缓解率为0%。
- 同时给药DL1组客观缓解率为40%,DL2b组为0%。
- 间歇给药DL2组7例(47%)发生3/4级治疗相关不良事件,客观缓解率为27%;DL1组客观缓解率为33%。
关键数值与推荐
- 同时给药最大耐受剂量:帕博利珠单抗200 mg每3周联合曲美替尼1.5 mg每日一次,含2周曲美替尼1.5 mg每日一次导入(同时给药DL2a)。
- 间歇给药最大耐受剂量:帕博利珠单抗200 mg每3周联合曲美替尼2 mg每日一次,含2周曲美替尼2 mg每日一次导入(间歇给药DL2)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type melanoma. PATIENTS AND METHODS: Patients received intermittent or concurrent dosing of pembrolizumab plus trametinib. Concurrent dosing was 2 or 4 weeks of trametinib run-in followed by concurrent pembrolizumab every 3 weeks (Q3W) plus trametinib once daily (QD). Intermittent dosing was 2 weeks of trametinib run-in followed by pembrolizumab plus intermittent trametinib (1 week off/2 weeks on). A 3 + 3 dose escalation was used, followed by dose confirmation. RESULTS: Forty-two patients were enrolled. No dose-limiting toxicities (DLTs) occurred at initial dose levels (DL). At subsequent DLs, 10 of 38 evaluable patients had DLTs. For concurrent dosing, MTD was pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD, with a 2-week trametinib 1.5 mg QD run-in (concurrent DL2a); in concurrent DL2a group, five (31%) patients had grade 3/4 treatment-related adverse events (TRAEs); the objective response rate (ORR) was 0%. ORR was 40% in concurrent DL1 and 0% in concurrent DL2b. For intermittent dosing, MTD was pembrolizumab 200 mg Q3W plus trametinib 2 mg QD with a 2-week trametinib 2 mg QD run-in (intermittent DL2); in the intermittent DL2 group, seven (47%) patients had grade 3/4 TRAEs; ORR was 27%. ORR in intermittent DL1 was 33%. CONCLUSIONS: MTDs for concurrent and intermittent dosing of pembrolizumab with trametinib were identified. The combination had limited antitumour activity, numerically higher ORR with intermittent versus concurrent dosing, and manageable safety. CLINICALTRIALS. GOV IDENTIFIER: NCT02130466.
引用
- Maio M, Carlino MS, Joshua AM, et al. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Eur J Cancer. 2021. PMID: 34801354. doi:10.1016/j.ejca.2021.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。